Kurtovic Jelica, Segal Isidor
Gastrointestinal and Liver unit, Prince of Wales Hospital, High Street, Randwick 2031, Australia.
Trop Gastroenterol. 2004 Jan-Mar;25(1):9-14.
Immune system is a major determinant of pathophysiology of inflammatory bowel disease (IBD), and cytokines are well known mediators of immune system. Recently, informations on pro-inflammatory cytokines and their role in IBD have led to development of potential therapeutic approach to manipulate these cytokines and there by inhibiting inflammation in IBD. These therapeutic approaches include inhibitors of the tumour necrosis factor (TNF)-alpha lymphocyte trafficking, type 1 T helper (Th1) cell polarization and nuclear factor type beta; immunoregulatory cytokines and various growth factors. Studies on these therapies have documented variable results and the outcomes of many clinical trials are awaited. However, these potential therapies, if become real may revolutionise approach in patients with IBD. Analysis of the inflammed mucosa from patients with Crohn disease (CD) and ulcerative colitis (UC) have shown increased expression of certain proinflammatory cytokines such as interleukin-1 (IL-1), interleukin 6 (IL-6) and TNF-alpha. The latter is important in the recruitment of neutrophils into inflammed tissue, a process which results from three physiological steps: (i) rolling, (ii) adhesion, and (iii) transendothelial migration. Understanding of the biology of chronic inflammation has expanded the therapies available for IBD and particularly CD. At present, the biological therapies that are being used in clinical practice or investigated for the treatment of IBD are predominantly proteins, usually delivered intravenously or subcutaneously. The therapies used include: 1. TNF-alpha inhibitors: infliximab, CDP 571, etanercept, onercept, CNI- 1493 and thalidomide. 2. Inhibitors of lymphocyte trafficking: natalizumab, LPD-02 and ICAM-1. 3. Inhibitors of Th1 polarization: monoclonal antibodies for IL-12, interferon (IFN)-gamma and anti IFN-gamma. 4. Immunoregulatory cytokines: IL-10 and IL-11. 5. Inhibitors of nuclear factor kappa (beta NF-kbeta.) 6. Growth factors: epidermal growth factor (EGF) and Keratinocyte growth factor (KGF).
免疫系统是炎症性肠病(IBD)病理生理学的主要决定因素,而细胞因子是免疫系统中众所周知的介质。最近,关于促炎细胞因子及其在IBD中的作用的信息促使人们开发出潜在的治疗方法来操纵这些细胞因子,从而抑制IBD中的炎症。这些治疗方法包括肿瘤坏死因子(TNF)-α淋巴细胞运输抑制剂、1型辅助性T(Th1)细胞极化抑制剂和核因子β抑制剂;免疫调节细胞因子和各种生长因子。对这些疗法的研究记录了不同的结果,许多临床试验的结果仍有待观察。然而,这些潜在的疗法如果成为现实,可能会彻底改变IBD患者的治疗方法。对克罗恩病(CD)和溃疡性结肠炎(UC)患者炎症黏膜的分析表明,某些促炎细胞因子如白细胞介素-1(IL-1)、白细胞介素6(IL-6)和TNF-α的表达增加。后者在中性粒细胞募集到炎症组织中起重要作用,这一过程由三个生理步骤组成:(i)滚动,(ii)黏附,以及(iii)跨内皮迁移。对慢性炎症生物学的理解扩展了IBD尤其是CD的可用治疗方法。目前,临床实践中正在使用或正在研究用于治疗IBD的生物疗法主要是蛋白质,通常通过静脉内或皮下给药。所使用的疗法包括:1. TNF-α抑制剂:英夫利昔单抗、CDP 571、依那西普、昂瑞普、CNI-1493和沙利度胺。2. 淋巴细胞运输抑制剂:那他珠单抗、LPD-02和细胞间黏附分子-1(ICAM-1)。3. Th1极化抑制剂:抗IL-12单克隆抗体、干扰素(IFN)-γ和抗IFN-γ。4. 免疫调节细胞因子:IL-10和IL-11。5. 核因子κ(βNF-κβ)抑制剂。6. 生长因子:表皮生长因子(EGF)和角质形成细胞生长因子(KGF)。